Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

16-09-2022 | ESMO 2022 | Conference coverage | Video

Sotorasib outperforms docetaxel in previously treated KRAS-mutated NSCLC

Melissa Johnson provides an overview of the CodeBreaK 200 study pitting sotorasib against docetaxel in patients who have received prior treatment for non-small-cell lung cancer with KRAS G12C mutations (2:59).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Related content

14-04-2022 | AACR 2022 | Conference coverage | News

2-year CodeBreaK 100 data point to sustained benefit of sotorasib

28-07-2022 | Liquid biopsy | News

ctDNA analysis can detect KRAS G12C mutations in people with cancer
Image Credits